P&L Forecasting/Project Valuation

Through advanced financial modelling techniques and deep knowledge about idiosyncrasies in Japan, e-Projection provides project valuation models specific to the Japanese pharmaceutical market in order for our clients to make informed decisions about how and when to approach the Japanese market.
This will be most relevant to biotech companies when negotiating the deal terms and structures of a local licensing agreement with Japanese pharmaceutical companies.

P&L assumptions

read more >

DCF-based valuations and risk adjustments

read more >

Commerciaization strategy/salesforce optimization

read more >

Leader

Takashi Yamano

Advisor: Sales & Marketing

Takashi Yamano brings nearly 40 years of major pharmaceutical industry experience, launching various drug products in the Japanese market within the areas of hematology, diabetes, allergy, cerebrovascular disease, osteoporosis, gastrointestinal and gynecology.
Takashi held numerous sales & marketing leadership positions over 20 years at Sanofi leading various multimillion-dollar projects including Lantus and Plavix.
He has served in a number of management roles associated with P&L responsibilities, enhancing expertise in sales force planning, SG&A management and supply chain optimization.
In this capacity, he maintains an extensive network among national/regional key opinion leaders across academia and the community of healthcare professionals, as well as wholesalers/distributors.

Case

Japan Opportunity Assessment

US-based biotech company developing phase II product in US/EU, trying to assess whether to expand development activities into Japan now or later. In planning for an IPO in a few months time, the company needed to ensure that investors understood the true global value of their product.

view more >

Business Development Support

US biotech company developing phase III product for treatment of a cardiac disease in a hospital setting. Seeking to investigate the Japanese market for their product, find local partners with expertise in the therapeutic area.

view more >

P&L assumptions

A robust SG&A and R&D cost assumptions takes expertise in the market, which will require the understanding about the cost per local subject to be included in the planned clinical trial(s) and labor/non-labor costs that will be needed after the product reaches the market.
e-Projection’s team of experts have the knowledge on the ground to make sound cost layouts with multiple scenarios based on various conditions and throughout the lifecycle of the product

DCF-based valuations and risk adjustments

Success rates upon each phase gate could be different in Japan, particularly in a standalone development plan.
We can adjust the attrition rate to to reflect the true expectation levels in order for our clients to understand the real value of the project and to reflect it into the deal terms in the case of a licensing agreement

Commerciaization strategy/salesforce optimization

Resource and budget plans are important for a successful product commercialization.
We can help our clients understand the number of the target physicians in the market and the size and the structure of the salesforce needed to approach them.
Also, e-Projection provides solutions of how to further optimize the sales team over the product life cycle in order to maximize the value of the product.

We help non-Japanese pharma/biotech companies
understand and expand into the Japanese market.